This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clemons, K. V. Articles by Stevens, D. A. Search for Related Content PubMed PubMed Citation Articles by Clemons, K. V. Articles by Stevens, D. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2002, p. 922-924, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.922-924.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Efficacy of Ravuconazole in Treatment of Systemic Murine Histoplasmosis

California Institute for Medical Research,¹ Division of Infectious Diseases, Department of Medicine, Santa Clara Valley Medical Center, San Jose, California 95128,² Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, California 94305³

Received 12 December 2000/ Returned for modification 18 January 2001/ Accepted 6 December 2001

Ravuconazole (RCZ) was evaluated for efficacy in comparison to fluconazole (FCZ) and itraconazole (ITZ) in murine models of disseminated histoplasmosis. All regimens tested prolonged survival (P < 0.05 to 0.0001). At equivalent doses of 50 mg/kg of body weight, RCZ and ITZ were equally effective and RCZ was more effective than FCZ (P = 0.02). Clearance of fungal burden from the livers and spleens of mice showed RCZ and ITZ at doses of 50 mg/kg to be efficacious but not curative. These data indicate that RCZ should be studied further.

This article has been cited by other articles:

• Pasqualotto, A. C., Denning, D. W. (2008). New and emerging treatments for fungal infections. J Antimicrob Chemother 61: i19-i30 [Abstract] [Full Text]  
• Wheat, L. J., Connolly, P., Smedema, M., Durkin, M., Brizendine, E., Mann, P., Patel, R., McNicholas, P. M., Goldman, M. (2006). Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother 57: 1235-1239 [Abstract] [Full Text]  
• Groll, A. H., Mickiene, D., Petraitis, V., Petraitiene, R., Kelaher, A., Sarafandi, A., Wuerthwein, G., Bacher, J., Walsh, T. J. (2005). Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. J Antimicrob Chemother 56: 899-907 [Abstract] [Full Text]  
• Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Garcia-Effron, G., Rodriguez-Tudela, J. L. (2004). In Vitro Activities of Ravuconazole and Four Other Antifungal Agents against Fluconazole-Resistant or -Susceptible Clinical Yeast Isolates. Antimicrob. Agents Chemother. 48: 3107-3111 [Abstract] [Full Text]  
• Petraitiene, R., Petraitis, V., Lyman, C. A., Groll, A. H., Mickiene, D., Peter, J., Bacher, J., Roussillon, K., Hemmings, M., Armstrong, D., Avila, N. A., Walsh, T. J. (2004). Efficacy, Safety, and Plasma Pharmacokinetics of Escalating Dosages of Intravenously Administered Ravuconazole Lysine Phosphoester for Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. Antimicrob. Agents Chemother. 48: 1188-1196 [Abstract] [Full Text]